{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:15:03Z","timestamp":1795029303698,"version":"4.10.2"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy \u2013 combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy \u2013 improves outcomes. However, few studies have directly compared this regimen with triple therapy (TACE plus targeted therapy and immunotherapy), and the optimal sequence of locoregional treatments within this regimen remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of HAIC-first quadruple therapy, TACE-first quadruple therapy, and triple therapy in patients with unresectable HCC (uHCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 158 patients with uHCC who received: HAIC-first quadruple therapy (HTTI,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a061), TACE-first quadruple therapy (THTI,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a041), or triple therapy (TTI,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a056). Tumor response was assessed with modified RECIST; progression-free survival (PFS), overall survival (OS), and safety were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The HTTI group achieved the highest objective response rate (ORR, 81.97%) and disease control rate (DCR, 96.72%), outperforming the THTI (ORR 73.17%, DCR 95.12%) and TTI groups (ORR 64.28%, DCR 85.71%). The median OS (mOS) was not reached in the HTTI group; the THTI group had a longer mOS (22.30\u00a0months) than the TTI group (19.00\u00a0months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.046). The median PFS (mPFS) was also longer in the HTTI group (12.90\u00a0months), compared to the THTI (10.40\u00a0months, P =\u00a00.042) group and TTI groups (9.30\u00a0months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Quadruple therapy increased grade 1 and 2 hypoalbuminemia, thrombocytopenia, and hand-foot syndrome, but grade 3 and 4 toxicities were similar across groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Quadruple therapy demonstrates superior efficacy compared to triple therapy for uHCC. Initiating treatment with HAIC followed by TACE appears more effective than the reverse sequence and merits prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002890","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:00:08Z","timestamp":1753196408000},"page":"6942-6960","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study"],"prefix":"10.1097","volume":"111","author":[{"given":"Juncheng","family":"Wan","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-3036","authenticated-orcid":false,"given":"Xudong","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Institute of Medical Imaging, Fudan University, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"R1-20260109","first-page":"221\u201331","article-title":"[Cancer incidence and mortality in China, 2022]","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R2-20260109","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"3994\u20134005","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"405\u201344","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"681\u201393","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1894\u2013905","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"25\u201334","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1163\u201373","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"203\u201315","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"216\u201332","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"R13-20260109","first-page":"475\u2013530","article-title":"National health commission of the people\u2019s Republic of China. Guidelines for the diagnosis and treatment of primary liver cancer (2024 edition)","volume":"33","year":"2024","journal-title":"Chin J Gen Surg"},{"key":"R14-20260109","first-page":"953\u201360","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"R15-20260109","first-page":"150\u201360","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"Jco"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"10443\u201352","DOI":"10.3748\/wjg.v21.i36.10443","article-title":"Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients","volume":"21","author":"Gao","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R17-20260109","first-page":"5455\u201365","article-title":"Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas","volume":"13","author":"Lin","year":"2023","journal-title":"Am J Cancer Res"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"1222\u201330","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"R19-20260109","first-page":"939\u201346","article-title":"[A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma]","volume":"30","author":"Li","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin J Hepatol"},{"key":"R20-20260109","first-page":"755","article-title":"Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma","volume":"73","author":"Lin","year":"2022","journal-title":"J Physiol Pharmacol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1298122","DOI":"10.3389\/fonc.2024.1298122","article-title":"The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"key":"R22-20260109","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"986\u201392","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (standards for QUality improvement reporting excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"052\u201360","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"358\u201380","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.7150\/jca.54650","article-title":"Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres\u00ae microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study","volume":"12","author":"Zhou","year":"2021","journal-title":"J Cancer"},{"key":"R27-20260109","first-page":"2004\u201311","article-title":"Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes","volume":"82","author":"Yoon","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"661\u201371","DOI":"10.21037\/hbsn-21-260","article-title":"Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)","volume":"10","author":"Lu","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"3501\u201308","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"721\u201329","DOI":"10.21037\/jgo-23-1006","article-title":"Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes","volume":"15","author":"Hien","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"e057","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg Open"},{"key":"R32-20260109","first-page":"1898\u2013908","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"3949\u201352","DOI":"10.1200\/JCO.2011.37.9651","article-title":"TACE and sorafenib: a good marriage?","volume":"29","author":"Abou-Alfa","year":"2011","journal-title":"J Clin Oncol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"977\u201390","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: opportunities for clinical development","volume":"21","author":"Ochoa de Olza","year":"2020","journal-title":"Lancet Oncol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"215\u201325","DOI":"10.1148\/radiol.211028","article-title":"Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model","volume":"303","author":"Tischfield","year":"2022","journal-title":"Radiology"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"445\u201358","DOI":"10.2147\/JHC.S506457","article-title":"Efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy plus lenvatinib for intermediate-stage hepatocellular carcinoma beyond up-to-seven: a multicentre, retrospective propensity score matching analysis","volume":"12","author":"Zhong","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"6670367","DOI":"10.1155\/2021\/6670367","article-title":"Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: a propensity score-matched analysis","volume":"2021","author":"Liu","year":"2021","journal-title":"Biomed Res Int"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"1445\u201358","DOI":"10.2147\/JHC.S339379","article-title":"Drug-eluting bead transarterial chemoembolization combined with FOLFOX-Based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma","volume":"8","author":"Huang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"477\u201388","DOI":"10.2147\/JHC.S452120","article-title":"Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular carcinoma","volume":"11","author":"Liu","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"477\u201383","DOI":"10.1002\/jgh3.12285","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: a propensity score-matching cohort study","volume":"4","author":"Guo","year":"2020","journal-title":"JGH Open"},{"key":"R42-20260109","first-page":"345\u201351","article-title":"Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk","volume":"18","author":"Wu","year":"2022","journal-title":"J Canc Res Ther"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/medicina57080779","article-title":"Hepatic arterial infusion chemotherapy followed by lipiodol infusion for advanced hepatocellular carcinoma with portal vein tumor thrombus: a single-center experience","volume":"57","author":"Chen","year":"2021","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm13010088","article-title":"New regimen of combining hepatic arterial infusion chemotherapy and lipiodol embolization in treating hepatocellular carcinoma with main portal vein invasion","volume":"13","author":"Li","year":"2022","journal-title":"J Pers Med"},{"key":"R45-20260109","first-page":"36\u201344","article-title":"Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis","volume":"29","author":"Zhang","year":"2017","journal-title":"Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu"},{"key":"R46-20260109","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4251\/wjgo.v12.i6.663","article-title":"Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma","volume":"12","author":"Liu","year":"2020","journal-title":"World J Gastrointestinal Oncol"},{"key":"R47-20260109","first-page":"564\u201371","article-title":"Transarterial chemoembolization followed by hepatic arterial infusion chemotherapy combined a tyrosine kinase inhibitor for treatment of large hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"key":"R48-20260109","doi-asserted-by":"crossref","first-page":"2501\u201307","DOI":"10.3748\/wjg.v24.i23.2501","article-title":"Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus","volume":"24","author":"Zhu","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"2405749","DOI":"10.1002\/advs.202405749","article-title":"Single-nucleus and spatial transcriptome profiling delineates the multicellular ecosystem in hepatocellular carcinoma after hepatic arterial infusion chemotherapy","volume":"12","author":"Huang","year":"2025","journal-title":"Adv Sci"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"4\u201331","DOI":"10.1007\/s12072-023-10599-6","article-title":"Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"key":"R51-20260109","doi-asserted-by":"crossref","first-page":"1267\u201375","DOI":"10.3748\/wjg.v17.i10.1267","article-title":"Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma","volume":"17","author":"Vogl","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R52-20260109","first-page":"1415\u201328","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study","volume":"11","author":"Liu","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"R53-20260109","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1186\/s12885-024-13164-y","article-title":"Elevated serum direct bilirubin is predictive of a poor prognosis for primary myelodysplastic syndrome","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"key":"R54-20260109","doi-asserted-by":"crossref","first-page":"892\u2013900","DOI":"10.18632\/oncotarget.23184","article-title":"Direct bilirubin levels are prognostic in non-small cell lung cancer","volume":"9","author":"Song","year":"2018","journal-title":"Oncotarget"},{"key":"R55-20260109","doi-asserted-by":"crossref","first-page":"560\u201375","DOI":"10.1007\/s12072-025-10777-8","article-title":"Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and\/or right atrium tumor thrombus","volume":"19","author":"Zhong","year":"2025","journal-title":"Hepatol Int"},{"key":"R56-20260109","doi-asserted-by":"crossref","first-page":"455\u201364","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"R57-20260109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12957-024-03396-4","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion","volume":"22","author":"Zhang","year":"2024","journal-title":"World J Surg Oncol"},{"key":"R58-20260109","doi-asserted-by":"crossref","first-page":"957\u201366","DOI":"10.1002\/ijc.34046","article-title":"Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome","volume":"151","author":"Watts","year":"2022","journal-title":"Int J Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:00:46Z","timestamp":1767963646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002890","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2025-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}